Streetbeat News

Earnings

MEDP

Medpace Holdings' shares are experiencing an upward trend following the announcement of Q4 earnings per share (EPS) results that surpassed expectations. Additionally, the company has provided EPS guidance for FY24 that exceeds analyst estimates.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 5:16 pm

SONY

Sony Group's shares are trading lower following the announcement of its Q3 financial results and a reduction in its FY23 sales forecast.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 5:15 pm

ROKU

VZIO

WMT

Walmart Inc is considering acquiring Vizio Holding Corp, causing volatility in Roku Inc's shares. Analysts provided mixed views on the impact of this potential deal on Roku and Vizio ahead of Roku's Q4 earnings. Some see it as a negative for Roku, potentially losing its position in Walmart's ecosystem, while others view it as an opportunity for Roku to leverage its large active account base.

Portfolio Pulse from Chris Katje

February 14, 2024 | 5:09 pm

LYFT

UBER

Lyft Inc (NASDAQ:LYFT) shares surged following strong Q4 results, with analysts adjusting their ratings and price targets. The company's strategy focusing on pricing, customer experience, and product improvements led to accelerated growth in rides and frequency. Analysts from Truist Securities, Piper Sandler, Wedbush, RBC Capital Markets, JPMorgan, BMO Capital Markets, and Needham provided insights, with most raising their price targets based on Lyft's performance and positive outlook for 2024. Lyft's competition with Uber Technologies Inc (NYSE:UBER) was also highlighted, noting Lyft's more stable competitive footing.

Portfolio Pulse from Priya Nigam

February 14, 2024 | 5:09 pm

PACB

Pacific Biosciences (NASDAQ:PACB) is scheduled to release its quarterly earnings report on February 15, 2024, with an estimated EPS of $-0.28. Investors are hopeful for a beat on this estimate and positive guidance for the next quarter. Historically, the company's share price has reacted variably to past earnings reports, with a notable 13.08% drop after last quarter's beat. Over the last year, PACB shares have declined by 40.83%, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 5:02 pm

TXG

10x Genomics (NASDAQ:TXG) is scheduled to release its quarterly earnings report on February 15, 2024, with an estimated EPS of $-0.36. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows that 10x Genomics has had a mixed performance in beating EPS estimates, with share price reactions varying accordingly. Currently, shares are trading at $46.78, marking a 6.47% decline over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 5:02 pm

WEN

Wendy's (NASDAQ:WEN) is anticipated to report a quarterly EPS of $0.23 on February 15, 2024. Investors are keen on not just the earnings beat but also the forward guidance. Wendy's has a history of surpassing EPS estimates, leading to positive stock price movements. However, the stock has seen a 16.23% decline over the last year, indicating long-term shareholder dissatisfaction.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 5:02 pm

AGIO

Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to release its quarterly earnings report on February 15, 2024, with an expected EPS of $-1.65. Historical data shows variable stock price reactions to past earnings reports, with a 7.1% increase following the last quarter's beat. Shares are currently trading at $25.15, reflecting a 4.61% decline over the past year. Investors are keen on both the earnings outcome and the company's future guidance.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 5:01 pm

APPN

Appian (NASDAQ:APPN) is scheduled to release its quarterly earnings report on February 15, 2024, with an estimated EPS of $-0.24. Analysts and investors will be closely watching for not only an earnings beat but also positive guidance for the next quarter. Historical data shows mixed reactions to past earnings reports, with share prices fluctuating post-announcement. Currently, Appian's shares are trading at $31.68, marking a 27.69% decrease over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 5:01 pm

BPMC

Blueprint Medicines (NASDAQ:BPMC) is anticipated to report a Q4 earnings per share (EPS) of $-2.04 on February 15, 2024. Analysts and investors are keen on whether the company will surpass this estimate and provide optimistic guidance for the next quarter. Historically, BPMC's stock price has shown varied reactions to its earnings performance, with a notable 72.24% increase over the last 52 weeks. The company's past earnings have occasionally beaten estimates, but this has not always led to positive stock price movements the following day.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 5:01 pm